Accessibility StatementSkip Navigation What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Inspire common stock during the class period because the Company allegedly misled investors regarding its Inspire V Device. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? According to the complaint, Inspire develops and manufactures an im ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Nutex Health Inc. following a class action complaint filed on August 22, 2025, concerning alleged breaches of fiduciary duties by the company's board of directors during the class period from August 8, 2024, to August 14, 2025 [1][2]. Summary by Sections Allegations - The complaint alleges that Nutex's management made materially false and misleading statements regarding the company's business and operations, including: - Engaging in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenues [2]. - Overstating the remediation of material weaknesses in internal controls over financial reporting [2]. - Improperly accounting for stock-based compensation obligations as equity instead of liabilities [2]. - Increased risk of failing to timely file financial reports with the SEC due to these issues [2]. - Overall, the company's business and financial prospects were overstated, making public statements materially false and misleading [2]. Next Steps for Investors - Long-term stockholders of Nutex are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims related to the allegations [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Vestis Corporation (NYSE:VSTS) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][6]. Company Overview - Vestis Corporation is facing scrutiny following a class action complaint filed on August 8, 2025, with a class period from May 2, 2024, to May 6, 2025 [1]. - The complaint alleges that the defendants made overwhelmingly positive statements while concealing material adverse facts about Vestis' business growth capabilities [6]. Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year [6]. - The company reported that its poor performance was due to "lost business in excess of new business" and "lower adds over stops," indicating challenges in customer retention and revenue growth [6]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [6].

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against AlloVir, Inc. on behalf of long-term stockholders following a class action complaint filed on March 19, 2024, concerning the period from March 22, 2022 to December 21, 2023 [2][7] - The investigation focuses on whether AlloVir's board of directors breached their fiduciary duties to the company [2] - The complaint alleges that AlloVir made materially false and misleading statements regarding its business and operations, particularly concerning the posoleucel Phase 3 studies [7] Company Details - AlloVir announced on December 22, 2023, that it would discontinue the posoleucel Phase 3 studies due to efficacy concerns, stating that pre-planned analyses indicated they would not meet their primary endpoints [7] - Following this announcement, AlloVir's stock price fell by $1.57 per share, or 67.38%, closing at $0.76 per share on December 22, 2023 [7]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marqeta, Inc. due to a class action lawsuit alleging that the company made false or misleading statements regarding its business outlook and regulatory challenges [1][2]. Group 1: Lawsuit Details - The class action complaint was filed on December 9, 2024, covering a Class Period from May 7, 2024, to November 4, 2024 [1]. - Allegations include that Marqeta understated regulatory challenges, leading to a necessary cut in guidance for Q4 2024, and that public statements made by the defendants were materially false or misleading [2]. Group 2: Next Steps for Investors - Long-term stockholders of Marqeta are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and the ongoing investigation [3]. Group 3: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation across various courts [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against LifeCore Biomedical, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Summary by Sections Investigation Details - The class action complaint was filed on July 29, 2024, covering a class period from October 7, 2020, to March 19, 2024 [1]. - Allegations include that LifeCore made materially false and misleading statements regarding its business operations and financial prospects [2]. - Specific claims include: 1. Deficient internal controls over financial reporting [2]. 2. Issuance of inaccurate financial statements requiring restatement [2]. 3. Ineffective remediation efforts regarding internal control deficiencies [2]. 4. Impaired ability to file periodic reports with the SEC, affecting NASDAQ compliance [2]. 5. Material overstatement of the company's financial position and prospects [2]. 6. Public statements being materially false and misleading throughout the class period [2]. Next Steps for Investors - Long-term stockholders of LifeCore are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and the ongoing investigation [3]. - Contact options include email and telephone, with no cost or obligation for inquiries [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4]. - The firm operates in multiple states, including New York, South Carolina, and California [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maison Solutions Inc. (NASDAQ: MSS) on behalf of long-term stockholders due to a class action complaint filed against the company, alleging breaches of fiduciary duties by the board of directors [1][7]. Group 1: Legal Investigation - The investigation is prompted by a class action complaint filed on January 2, 2024, concerning Class A common stock related to the company's initial public offering (IPO) and securities from October 5, 2023, to December 15, 2023 [1][7]. - The complaint alleges that the Offering Documents were negligently prepared, containing untrue statements of material fact and failing to disclose necessary facts, including the engagement of auditors and underwriters with poor track records and undisclosed related party transactions [7]. Group 2: IPO Details - Maison Solutions conducted its IPO between October 5, 2023, and October 10, 2023, issuing 2,500,000 common shares at an offering price of $4.00 per share, resulting in approximately $10 million in proceeds before expenses [7]. - The Offering Documents, which included the registration statement and prospectus, were declared effective on September 29, 2023, after multiple amendments [7].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Zeta Global Holdings Corp. due to allegations of misleading financial practices and data collection methods that may have harmed long-term stockholders [2][4]. Group 1: Allegations Against Zeta - A report by Culper Research claims that Zeta's data collection and financial reporting integrity is compromised by two main issues: the use of "two-way" contracts with third-party consent farms and the operation of deceptive websites to collect consumer data [3]. - The report alleges that Zeta's revenue growth is artificially inflated through these practices, including "round-tripping" of revenue and reliance on predatory consent farms for data collection [3][4]. - Following the report, Zeta's stock price dropped by $10.46, or 37.07%, closing at $17.76 per share on November 13, 2024, with unusually high trading volume [3]. Group 2: Class Action Complaint - The class action complaint filed against Zeta alleges that the company's executives made materially false and misleading statements and failed to disclose adverse facts about its business operations and prospects [4]. - Specific allegations include the use of two-way contracts to inflate financial results, engagement in round-trip transactions, and reliance on predatory consent farms for user data collection, which have driven nearly all of Zeta's growth [4]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is encouraging long-term stockholders of Zeta to contact them for discussions regarding their legal rights and potential claims related to the allegations [1][5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against AST SpaceMobile, Inc. (NASDAQ: ASTS) on behalf of long-term stockholders due to a class action complaint filed against the company, alleging breaches of fiduciary duties by the board of directors [2][5]. Group 1: Company Performance and Issues - On April 1, 2024, SpaceMobile announced that the production of five Block 1 BlueBird satellites was delayed due to issues with two suppliers, pushing the expected launch from the first quarter of 2024 to between July and August 2024 [3]. - Following this announcement, SpaceMobile's stock price dropped by $0.62, or 23.6%, closing at $2.01 per share on April 2, 2024, with unusually high trading volume [4]. Group 2: Legal Actions and Allegations - The class action complaint alleges that during the class period from November 14, 2023, to April 1, 2024, SpaceMobile's executives made materially false and misleading statements regarding the company's business and operations, failing to disclose significant production issues with the Block 1 BlueBird satellites [5]. - The complaint specifically states that the defendants did not inform investors about the negative impact on production from suppliers, the incomplete status of the satellites, and the resulting delay in the launch schedule, which rendered previous positive statements misleading [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against ModivCare, Inc. on behalf of long-term stockholders following a class action complaint alleging misleading statements and omissions regarding the company's cash flow stability [1][2]. Group 1: Legal Investigation - A class action complaint was filed against ModivCare on January 29, 2025, with a class period from November 3, 2022, to September 15, 2024 [1]. - The investigation focuses on whether ModivCare's board of directors breached their fiduciary duties to the company [1]. Group 2: Stock Performance Impact - During the class period, ModivCare allegedly made misleading statements about its contracts' ability to stabilize cash flow, leading to significant stock price declines as the truth emerged [2]. - On September 16, 2024, ModivCare revised its 2024 Adjusted EBITDA guidance from $185-$195 million to $170-$180 million, resulting in a stock price drop of $1.40, or nearly 10%, from $14.12 to $12.72 per share [2].